TOP TEN perturbations for 38391_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38391_at
Selected probe(set): 201850_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38391_at (201850_at) across 6674 perturbations tested by GENEVESTIGATOR:
CD44s overexpr. study 1 / normal HEK-293 cell sample
Relative Expression (log2-ratio):5.1427126Number of Samples:3 / 3
Experimental | CD44s overexpr. study 1 |
Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression. | |
Control | normal HEK-293 cell sample |
Untransfected, native human embryonic kidney cell line HEK-293 cell samples. |
SKVCR2.0 / SK-OV-3
Relative Expression (log2-ratio):4.6941586Number of Samples:2 / 2
Experimental | SKVCR2.0 |
Human metastatic cancer cell line derived from the ascites of a patent with adenocarcinoma of the ovary. Vincristine-resistant derivative of the ovarian adenocarcinoma cell line SKOV3 capable of growing in media with 2.0 µg/ml vincristine drug. Parental cell line:: SK-OV-3 Synonyms:SKVCR 2.0; SK VCR 2 Cellosaurus code: | |
Control | SK-OV-3 |
Human metastatic cancer cell line derived from the ascites of a patient with ovarian serous cystadenocarcinoma. Synonyms:SKOV-3; SK.OV.3; SKOV3; SKO3 Cellosaurus code: |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):4.4565983Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.452589Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):3.826151Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS5) |
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):3.8058815Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal T-cell sample |
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):3.7389488Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-3.4004116Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Relative Expression (log2-ratio):-3.3927011Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; osteosarcoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted). |
ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):3.3728561Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |